We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: low-dose IL-2
MedXY News
EnglishTag

low-dose IL-2

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
Allergy & ImmunologyALSclinical trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY|Dec 6, 2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid
Dermatologylow-dose IL-2Regulatory T cells

Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid

By MedXY|Dec 6, 2025

A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, suppo

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Allergy & ImmunologyAlzheimer's diseaselow-dose IL-2

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

By MedXY|Dec 6, 2025

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo

Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases
Allergy & Immunologyautoimmunityclinical trials

Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases

By MedXY|Oct 1, 2025

Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfun

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities